[6-K] GH Research PLC Current Report (Foreign Issuer)

Rhea-AI Filing Summary

GH Research PLC reported that posters from its GH001-TRD-201 clinical program were accepted for presentation at the 64th American College of Neuropsychopharmacology annual meeting, scheduled for January 12–15, 2026 in Nassau, Bahamas. The submission set includes three abstracts: suicidal ideation and behavior in treatment-resistant depression (Ex. 99.1; presenter Sanjay J. Mathew), rapid antidepressant effects of inhaled GH001 in treatment-resistant depression from a Phase 2b randomized trial with 6‑month follow-up (Ex. 99.2; presenter Lisa Harding), and efficacy and safety of inhaled mebufotenin (GH001) in Bipolar II depression from a Phase 2a trial (Ex. 99.3; presenter Andreas Reif).

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

GH Research PLC announces the acceptance of posters related to its GH001-TRD-201 clinical trial at the 64^th American College of Neuropsychopharmacology (ACNP) annual meeting (the “Congress”), which is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas.

A copy of the abstract for the poster to be presented by Sanjay J. Mathew during the Congress is attached hereto as Exhibit 99.1.

A copy of the abstract for the poster to be presented by Lisa Harding during the Congress is attached hereto as Exhibit 99.2.

A copy of the abstract for the poster to be presented by Andreas Reif during the Congress, is attached hereto as Exhibit 99.3.

1

EXHIBIT INDEX

99.1	Abstract for poster to be presented by Sanjay J. Mathew with Title: Suicidal Ideation and Behavior in Patients With Treatment-Resistant Depression Treated With GH001
99.2	Abstract for poster to be presented by Lisa Harding with Title: Rapid Antidepressant Effects of Inhaled GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized Controlled Trial with 6-Month Follow-Up
99.3	Abstract for poster to be presented by Andreas Reif with Title: Efficacy and Safety of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode: Results from a Phase 2a Clinical Trial

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: October 17, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3

FAQ

What did GH Research (GHRS) announce in this 6-K?

The company announced acceptance of posters related to its GH001-TRD-201 clinical program for presentation at the 64th ACNP annual meeting, with three abstracts attached as exhibits.

When and where is the ACNP meeting for GHRS’s presentations?

The ACNP meeting is scheduled for January 12–15, 2026, in Nassau, Bahamas.

Which GH001 studies are highlighted by GHRS?

Abstracts cover treatment-resistant depression (including suicidal ideation/behavior and a Phase 2b RCT with 6‑month follow-up) and Bipolar II depression (Phase 2a) with inhaled GH001.

Who are the presenters for GHRS’s ACNP posters?

Presenters are Sanjay J. Mathew (Ex. 99.1), Lisa Harding (Ex. 99.2), and Andreas Reif (Ex. 99.3).

What are the exhibit numbers for GHRS’s ACNP abstracts?

Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3 contain the poster abstracts.

Does the filing include clinical results for GH001?

It provides abstracts as exhibits; the main notice states acceptance of posters for presentation at ACNP.